SECURITIES AND EXCHANGE COMMISSION
                           Washington, D.C. 20549-1004

                                    FORM 8-K
                    CURRENT REPORT PURSUANT TO SECTION 13 OF
                       THE SECURITIES EXCHANGE ACT OF 1934

         Date of Report (date of earliest event reported): July 24, 2003

                           Ciphergen Biosystems, Inc.
             (Exact name of Registrant as specified in its charter)

            Delaware                    000-31617              33-059-5156
(State or other jurisdiction of        [Commission           (I.R.S. Employer
 incorporation or organization)        File Number]       Identification Number)

                              6611 Dumbarton Circle
                                Fremont, CA 94555
                    (Address of principal executive offices)

                                 (510) 505-2100
              (Registrant's telephone number, including area code)


      The information in this Current Report on Form 8-K, including the
exhibits, is furnished pursuant to Item 12 - Results of Operations and Financial
Condition and shall not be deemed "filed" for the purposes of Section 18 of the
Securities Exchange Act of 1934, as amended, or otherwise subject to the
liabilities under that Section. Furthermore, the information in this Current
Report on Form 8-K, including the exhibits, shall not be deemed to be
incorporated by reference into the filings of Ciphergen Biosystems, Inc. under
the Securities Act of 1933, as amended.

Item 9.  Regulation FD Disclosure (pursuant to "Item 12. Results of Operations
         and Financial Condition").

      A copy of the press release issued July 24, 2003 by the Registrant
announcing Second Quarter 2003 earnings is furnished under Item 12 of this
Current Report on Form 8-K as Exhibit 99.1. The press release contains an
adjustment for a non-recurring expense relating to a recent settlement
litigation (a non-GAAP financial measure), as well as the required
reconciliation of such non-GAAP financial measure with the corresponding GAAP
measure. Management believes that the adjustment enhances investors' ability to
compare the Company's results of operations for the three and six month periods
ended June 30, 2003 to its results for historic and future quarterly periods.
Management relies on this presentation internally for purposes of comparing such
periods.


                                    SIGNATURE

      Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.

                                          Ciphergen Biosystems, Inc.
                                          (Registrant)

Date:  July 24, 2003                      By: /s/ William Rich
                                          -------------------------------------
                                          William E. Rich
                                          President and Chief Executive Officer



                                  EXHIBIT INDEX

Exhibit
Number                              Description
- --------------------------------------------------------------------------------
99.1        Press Release issued by Ciphergen Biosystems, Inc. on July 24, 2003